{"title": "Fluzone Quadrivalent, Fluzone High-Dose Quadrivalent", "author": "Center; Research", "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/fluzone-quadrivalent-fluzone-high-dose-quadrivalent-fluzone-intradermal-quadrivalent-fluzone", "hostname": "fda.gov", "description": "Sanofi Pasteur Inc.", "sitename": "FDA", "date": "2023-07-14", "cleaned_text": "High-Dose Quadrivalent: For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. - Fluzone High-Dose Quadrivalent Southern Hemisphere: For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the Vaccine. Approved for use in persons 65 years of age and older. - Fluzone Quadrivalent: For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It is approved for use in persons 6 months of age and older. - Fluzone Intradermal Quadrivalent: For active immunization of persons 18 through 64 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. - Fluzone Quadrivalent Southern Hemisphere: for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. (1) It is approved for use in persons 6 months of age and older. Product Information [Package Insert - Fluzone Quadrivalent](/media/170019/download?attachment) [Package Insert - Quadrivalent Southern Hemisphere](/media/165357/download?attachment) [Package Insert and Insert - Fluzone Intradermal Sheet - Fluzone Quadrivalent Southern Hemisphere](/media/120054/download?attachment) Supporting Documents [July 12, - Fluzone Quadrivalent and Fluzone High-Dose](/media/170020/download?attachment) [February 22, 2023 Approval Letter - Fluzone High Dose Quadrivalent](/media/165616/download?attachment) [February 13, 2023 Approval Letter - Fluzone High-Dose and 2020 Approval Letter - Fluzone Quadrivalent 4, 2019 Approval Letter - Quadrivalent](/media/132239/download?attachment) High-Dose](/media/128577/download?attachment) [February 4, 2019 Approval Letter - Fluzone Quadrivalent Southern Hemisphere](/media/120053/download?attachment) To include the 2019 Southern Hemisphere FluzoneQuadrivalent formulation and associated labeling revisions. [January 23, 2019 Approval Letter - Fluzone Quadrivalent](/media/119855/download?attachment) To include the use of a 0.5 mL single dose presentation of Fluzone Quadrivalent formulation in children 6 to 36 months of age. [January 18, 2019 Summary Basis of Regulatory Action](/media/119854/download?attachment) [Clinical Review - Fluzone Quadrivalent](/media/119853/download?attachment) [Statistical Review Quadrivalent](/media/119858/download?attachment) 2018 Approval Letter- Fluzone-Quadrivalent](/media/114405/download?attachment) To include the 2018-2019 Northern Hemisphere formulation and associated labeling revisions. [January 10, 2018 Approval Letter - Fluzone](/media/110589/download?attachment) To include the 2018 Southern Hemisphere Formulation and Associated Labeling Revisions. [February 9, 2017 Approval Letter - Fluzone Southern Hemisphere Formulation](/media/105101/download?attachment) To include the 2017 Southern Hemisphere Formulation and Associated Labeling Revisions. [Supporting Documents older than three "}